Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM0501 in advanced solid tumors
NCT06331559Phase 1Terminated
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Mar 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SIM0501 in solid tumor (advanced stage) (4 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Dose-limiting toxicity at 28 days and Adverse events. Started Mar 2024; status: terminated.
02
Drugs
SIM0501
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06331559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06331559.